# Francasco Patti

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5708951/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 319 papers | 11,789 citations | 38742 50 h-index | 46799 89 g-index |
| 330 all docs | 330 docs citations | 330 times ranked | 9579 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986. | 10.2 | 472 |
| 2 | Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. New England Journal of Medicine, 2019, 381, 2114-2124. | 27.0 | 383 |
| 3 | Diseaseâ€Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology, 2021, 89, 780-789. | 5.3 | 370 |
| 4 | The Raoâ€™s Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population. Multiple Sclerosis Journal, 2006, 12, 787-793. | 3.0 | 343 |
| 5 | The Global Adherence Project (GAP): a multicenter observational study on adherence to diseaseâ€modifying therapies in patients with relapsingâ€remitting multiple sclerosis. European Journal of Neurology, 2011, 18, 69-77. | 3.3 | 299 |
| 6 | The prevalence of pain in multiple sclerosis. Neurology, 2004, 63, 919-921. | 1.1 | 274 |
| 7 | Cognitive and psychosocial features of childhood and juvenile MS. Neurology, 2008, 70, 1891-1897. | 1.1 | 251 |
| 8 | Neuropsychological features in childhood and juvenile multiple sclerosis. Neurology, 2014, 83, 1432-1438. | 1.1 | 227 |
| 9 | Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Multiple Sclerosis Journal, 2017, 23, 1258-1267. | 3.0 | 209 |
| 10 | Cognitive and psychosocial features in childhood and juvenile MS. Neurology, 2010, 75, 1134-1140. | 1.1 | 198 |
| 11 | Cognitive-motor dual-task interference: A systematic review of neural correlates. Neuroscience and Biobehavioral Reviews, 2017, 75, 348-360. | 6.1 | 179 |
| 12 | Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsingâ€“remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Multiple Sclerosis Journal, 2009, 15, 779-788. | 3.0 | 172 |
| 13 | Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Preference and Adherence, 2010, 4, 1. | 1.8 | 146 |
| 14 | Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology, 2005, 65, 280-285. | 1.1 | 142 |
| 15 | Pregnancy and fetal outcomes after interferon-Î² exposure in multiple sclerosis. Neurology, 2010, 75, 1794-1802. | 1.1 | 142 |
| 16 | Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology, 2011, 77, 145-150. | 1.1 | 135 |
| 17 | Cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 2-8. | 3.0 | 132 |
| 18 | Realâ€life impact of early interferonÎ² therapy in relapsing multiple sclerosis. Annals of Neurology, 2009, 66, 513-520. | 5.3 | 132 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Measuring the cost of cognitive-motor dual tasking during walking in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 123-131. | 3.0 | 117 |
| 20 | Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 783-791. | 3.0 | 113 |
| 21 | Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. Journal of Neuroimmunology, 1996, 70, 87-90. | 2.3 | 112 |
| 22 | Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2019, 18, 845-856. | 10.2 | 110 |
| 23 | Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e823-e831. | 1.1 | 102 |
| 24 | Health-related quality of life and depression in an Italian sample of multiple sclerosis patients. Journal of the Neurological Sciences, 2003, 211, 55-62. | 0.6 | 99 |
| 25 | Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Multiple Sclerosis Journal, 2005, 11, 420-424. | 3.0 | 99 |
| 26 | Lithium carbonate in amyotrophic lateral sclerosis. Neurology, 2010, 75, 619-625. | 1.1 | 90 |
| 27 | Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsingâ€"remitting multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 68-77. | 3.0 | 89 |
| 28 | Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 944-951. | 1.9 | 88 |
| 29 | Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology, 2001, 57, 342-344. | 1.1 | 86 |
| 30 | Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. JAMA Neurology, 2021, 78, 414. | 9.0 | 86 |
| 31 | DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744. | 3.7 | 86 |
| 32 | The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. Journal of the Neurological Sciences, 2008, 269, 49-53. | 0.6 | 85 |
| 33 | Rituximab for the treatment of multiple sclerosis: a review. Journal of Neurology, 2022, 269, 159-183. | 3.6 | 85 |
| 34 | Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurology, 2012, 12, 124. | 1.8 | 82 |
| 35 | CIRCULATING SERUM LEVELS OF IL-1ra IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS ARE NORMAL DURING REMISSION PHASES BUT SIGNIFICANTLY INCREASED EITHER DURING EXACERBATIONS OR IN RESPONSE TO IFN-Î² TREATMENT. Cytokine, 1996, 8, 395-400. | 3.2 | 81 |
| 36 | Caregiver quality of life in multiple sclerosis: a multicentre Italian study. Multiple Sclerosis Journal, 2007, 13, 412-419. | 3.0 | 78 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurology, 2012, 12, 165. | 1.8 | 78 |
| 38 | Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 329-334. | 3.0 | 77 |
| 39 | Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain, 2015, 138, 3275-3286. | 7.6 | 76 |
| 40 | Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?. Journal of Neurology, 2008, 255, 1250-1253. | 3.6 | 74 |
| 41 | Blood levels of transforming growth factor-beta 1 (TGF-Î²1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-Î²1b). Clinical and Experimental Immunology, 1998, 113, 96-99. | 2.6 | 72 |
| 42 | Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurological Sciences, 2009, 30, 193-199. | 1.9 | 68 |
| 43 | Unmet Needs of People with Severe Multiple Sclerosis and Their Carers: Qualitative Findings for a Home-Based Intervention. PLoS ONE, 2014, 9, e109679. | 2.5 | 67 |
| 44 | Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 845-850. | 1.9 | 66 |
| 45 | Headache and Multiple Sclerosis: A Population-Based Case-Control Study in Catania, Sicily. Cephalalgia, 2008, 28, 1163-1169. | 3.9 | 64 |
| 46 | Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study. Multiple Sclerosis Journal, 2010, 16, 742-748. | 3.0 | 63 |
| 47 | Prevalence and incidence of multiple sclerosis in Catania, Sicily. Neurology, 2001, 56, 62-66. | 1.1 | 60 |
| 48 | The Italian multiple sclerosis register. Neurological Sciences, 2019, 40, 155-165. | 1.9 | 59 |
| 49 | COVID-19 Severity in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, . | 6.0 | 57 |
| 50 | The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 620-626. | 3.0 | 56 |
| 51 | Longâ€Term Safety and Efficacy of Eculizumab in Aquaporinâ€4 <scp>IgGâ€Positive NMOSD</scp>. Annals of Neurology, 2021, 89, 1088-1098. | 5.3 | 55 |
| 52 | Prevalence of patient-reported dysphagia in multiple sclerosis patients: An Italian multicenter study (using the DYMUS questionnaire). Journal of the Neurological Sciences, 2013, 331, 94-97. | 0.6 | 53 |
| 53 | Subcutaneous Interferon Î²-1a May Protect against Cognitive Impairment in Patients with Relapsingâ€“Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study. PLoS ONE, 2013, 8, e74111. | 2.5 | 53 |
| 54 | Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain, 2020, 143, 3013-3024. | 7.6 | 53 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Review of Neurotherapeutics, 2014, 14, 1029-1042. | 2.8 | 52 |
| 56 | Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 404-407. | 1.9 | 49 |
| 57 | Botulinum toxin improves dysphagia associated with multiple sclerosis. European Journal of Neurology, 2011, 18, 486-490. | 3.3 | 48 |
| 58 | Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110195. | 3.5 | 48 |
| 59 | Lateâ€onset and youngâ€onset relapsingâ€remitting multiple sclerosis: evidence from a retrospective longâ€term followâ€up study. European Journal of Neurology, 2018, 25, 1425-1431. | 3.3 | 47 |
| 60 | Possible increasing risk of multiple sclerosis in Catania, Sicily. Neurology, 2005, 65, 1259-1263. | 1.1 | 46 |
| 61 | Prevalence and incidence of cognitive impairment in multiple sclerosis: a population-based survey in Catania, Sicily. Journal of Neurology, 2015, 262, 923-930. | 3.6 | 46 |
| 62 | Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory. PLoS ONE, 2016, 11, e0160261. | 2.5 | 46 |
| 63 | Heme oxygenase-1 expression in peripheral blood mononuclear cells correlates with disease activity in multiple sclerosis. Journal of Neuroimmunology, 2013, 261, 82-86. | 2.3 | 45 |
| 64 | Gray Matters in Multiple Sclerosis: Cognitive Impairment and Structural MRI. Multiple Sclerosis International, 2014, 2014, 1-9. | 0.8 | 45 |
| 65 | Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. Journal of Neurology, 2016, 263, 1727-1735. | 3.6 | 45 |
| 66 | Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. Journal of Neurology, 2018, 265, 828-835. | 3.6 | 45 |
| 67 | Subcortical Deep Gray Matter Pathology in Patients with Multiple Sclerosis Is Associated with White Matter Lesion Burden and Atrophy but Not with Cortical Atrophy: A Diffusion Tensor MRI Study. American Journal of Neuroradiology, 2014, 35, 912-919. | 2.4 | 44 |
| 68 | Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsingâ€“remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). Journal of Neurology, 2017, 264, 2436-2449. | 3.6 | 44 |
| 69 | Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurology, The, 2022, 21, 608-619. | 10.2 | 44 |
| 70 | Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. Neurological Sciences, 2011, 32, 1223-1231. | 1.9 | 43 |
| 71 | Quality of life, depression and fatigue in mildly disabled patients with relapsingâ€“remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive) Tj ETQq1 1 0.784314 rgBT /Overlock | 3.6 | 43 |
| 72 | Migraine causes retinal and choroidal structural changes: evaluation with ocular coherence tomography. Journal of Neurology, 2017, 264, 494-502. | 3.6 | 43 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Pesticide exposure assessed through agricultural crop proximity and risk of amyotrophic lateral sclerosis. Environmental Health, 2017, 16, 91. | 4.0 | 43 |
| 74 | No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. Journal of Neurology, 2018, 265, 2851-2860. | 3.6 | 43 |
| 75 | Psychosocial issue in children and adolescents with multiple sclerosis. Neurological Sciences, 2010, 31, 467-470. | 1.9 | 42 |
| 76 | Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. Multiple Sclerosis Journal, 2013, 19, 1508-1517. | 3.0 | 42 |
| 77 | Environmental and Occupational Risk Factors of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Study. International Journal of Environmental Research and Public Health, 2020, 17, 2882. | 2.6 | 42 |
| 78 | Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. Functional Neurology, 2009, 24, 159-62. | 1.3 | 42 |
| 79 | Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 2021, 96, . | 1.1 | 41 |
| 80 | Predictors of quality of life among patients with multiple sclerosis: An Italian cross-sectional study. Journal of the Neurological Sciences, 2007, 252, 121-129. | 0.6 | 40 |
| 81 | The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis. Cells, 2019, 8, 1114. | 4.1 | 40 |
| 82 | Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. Journal of Clinical Psychology in Medical Settings, 2016, 23, 33-52. | 1.4 | 39 |
| 83 | Aging with multiple sclerosis: prevalence and profile of cognitive impairment. Neurological Sciences, 2019, 40, 1651-1657. | 1.9 | 39 |
| 84 | Frequency and severity of headache is worsened by Interferon-Î² therapy in patients with multiple sclerosis. Acta Neurologica Scandinavica, 2012, 125, 91-95. | 2.1 | 38 |
| 85 | Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. Multiple Sclerosis Journal, 2019, 25, 399-407. | 3.0 | 38 |
| 86 | Clinical and Lifestyle Factors and Risk of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Study. International Journal of Environmental Research and Public Health, 2020, 17, 857. | 2.6 | 38 |
| 87 | Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain, 2022, 145, 2796-2805. | 7.6 | 38 |
| 88 | The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. Journal of the Neurological Sciences, 2014, 337, 67-73. | 0.6 | 37 |
| 89 | Cognitive assessment in multiple sclerosisâ€"an Italian consensus. Neurological Sciences, 2018, 39, 1317-1324. | 1.9 | 37 |
| 90 | SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Multiple Sclerosis Journal, 2022, 28, 1034-1040. | 3.0 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Increasing frequency of multiple sclerosis in Catania, Sicily: a 30-year survey. Multiple Sclerosis Journal, 2011, 17, 273-280. | 3.0 | 36 |
| 92 | An update on idiopathic intracranial hypertension in adults: a look at pathophysiology, diagnostic approach and management. Journal of Neurology, 2021, 268, 3249-3268. | 3.6 | 36 |
| 93 | Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs. Drug Safety, 2016, 39, 1163-1174. | 3.2 | 35 |
| 94 | Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 663-674. | 3.0 | 35 |
| 95 | Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience. Multiple Sclerosis and Related Disorders, 2019, 27, 324-326. | 2.0 | 35 |
| 96 | The epidemiology of amyotrophic lateral sclerosis in the Mount Etna region: a possible pathogenic role of volcanogenic metals. European Journal of Neurology, 2016, 23, 964-972. | 3.3 | 34 |
| 97 | Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739. | 5.3 | 34 |
| 98 | Multiple sclerosis in Italy: cost-of-illness study. Neurological Sciences, 2011, 32, 787-794. | 1.9 | 33 |
| 99 | Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study. Multiple Sclerosis Journal, 2018, 24, 1234-1242. | 3.0 | 33 |
| 100 | Neuropsychological, neuroradiological and clinical findings in multiple sclerosis. A 3 year follow-up study. European Journal of Neurology, 1998, 5, 283-286. | 3.3 | 32 |
| 101 | The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1741-1749. | 3.0 | 32 |
| 102 | Early use of high-efficacy diseaseâ€'modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. Journal of Neurology, 2022, 269, 5382-5394. | 3.6 | 32 |
| 103 | Lights and Shadows of Cyclophosphamide in the Treatment of Multiple Sclerosis. Autoimmune Diseases, 2011, 2011, 1-14. | 0.6 | 31 |
| 104 | Duloxetine Is Effective in Treating Depression in Multiple Sclerosis Patients. Clinical Neuropharmacology, 2013, 36, 114-116. | 0.7 | 31 |
| 105 | The Raoâ€™s Brief Repeatable Battery version B: normative values with age, education and gender corrections in an Italian population. Neurological Sciences, 2014, 35, 79-82. | 1.9 | 31 |
| 106 | Lesion Load May Predict Long-Term Cognitive Dysfunction in Multiple Sclerosis Patients. PLoS ONE, 2015, 10, e0120754. | 2.5 | 31 |
| 107 | Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. PLoS ONE, 2016, 11, e0153466. | 2.5 | 31 |
| 108 | Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis. SSRN Electronic Journal, 0, , . | 0.4 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Risk of Getting COVID-19 in People With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, . | 6.0 | 31 |
| 110 | Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. Journal of Neurology, 2004, 251, 1502-1506. | 3.6 | 30 |
| 111 | The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsingâ€“remitting multiple sclerosis patients. Journal of Neurology, 2005, 252, 1255-1261. | 3.6 | 30 |
| 112 | Determinants of Sexual Impairment in Multiple Sclerosis in Male and Female Patients with Lower Urinary Tract Dysfunction: Results from an Italian Crossâ€Sectional Study. Journal of Sexual Medicine, 2014, 11, 2406-2413. | 0.6 | 30 |
| 113 | Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study. Multiple Sclerosis Journal, 2014, 20, 220-226. | 3.0 | 30 |
| 114 | Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurological Sciences, 2014, 35, 307-316. | 1.9 | 30 |
| 115 | Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. Expert Review of Neurotherapeutics, 2015, 15, 803-824. | 2.8 | 30 |
| 116 | Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Neurological Sciences, 2017, 38, 1849-1858. | 1.9 | 30 |
| 117 | Beyond Disease: Happiness, Goals, and Meanings among Persons with Multiple Sclerosis and Their Caregivers. Frontiers in Psychology, 2017, 8, 2216. | 2.1 | 30 |
| 118 | Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642092268. | 3.5 | 30 |
| 119 | Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. Multiple Sclerosis Journal, 2022, 28, 2106-2111. | 3.0 | 30 |
| 120 | Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1355-1359. | 1.9 | 29 |
| 121 | Symptoms, Prevalence and Impact of Multiple Sclerosis in Younger Patients: A Multinational Survey. Neuroepidemiology, 2014, 42, 211-218. | 2.3 | 29 |
| 122 | Botulinum Toxin A for Sialorrhoea Associated with Neurological Disorders: Evaluation of the Relationship between Effect of Treatment and the Number of Glands Treated. Toxins, 2018, 10, 55. | 3.4 | 29 |
| 123 | Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 38, 101868. | 2.0 | 29 |
| 124 | Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. Acta Neurologica Scandinavica, 2006, 113, 241-247. | 2.1 | 28 |
| 125 | Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial. Trials, 2015, 16, 184. | 1.6 | 28 |
| 126 | A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. Journal of the Neurological Sciences, 2004, 223, 69-71. | 0.6 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Mutation analysis of the SPG4 gene in Italian patients with pure and complicated forms of spastic paraplegia. Journal of the Neurological Sciences, 2010, 288, 96-100. | 0.6 | 27 |
| 128 | Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurology, 2014, 14, 114. | 1.8 | 27 |
| 129 | Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1431-1442. | 3.0 | 27 |
| 130 | A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives. International Journal of Molecular Sciences, 2016, 17, 1725. | 4.1 | 27 |
| 131 | Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis. European Journal of Neurology, 2019, 26, 41-50. | 3.3 | 27 |
| 132 | Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1297-1303. | 1.9 | 27 |
| 133 | Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. Clinical and Experimental Immunology, 2009, 159, 159-168. | 2.6 | 26 |
| 134 | Treatment of cognitive impairment in patients with multiple sclerosis. Expert Opinion on Investigational Drugs, 2012, 21, 1679-1699. | 4.1 | 26 |
| 135 | Low quality of life and psychological wellbeing contrast with moderate perceived burden in carers of people with severe multiple sclerosis. Journal of the Neurological Sciences, 2016, 366, 139-145. | 0.6 | 26 |
| 136 | Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879640. | 3.5 | 26 |
| 137 | Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort. Frontiers in Neurology, 2019, 10, 337. | 2.4 | 26 |
| 138 | Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Neurology, 2021, 78, 726. | 9.0 | 26 |
| 139 | Multiple Sclerosis and CCSVI: A Population-Based Case Control Study. PLoS ONE, 2012, 7, e41227. | 2.5 | 25 |
| 140 | Restless legs syndrome and multiple sclerosis: a population based caseâ^'control study in Catania, Sicily. European Journal of Neurology, 2015, 22, 1018-1021. | 3.3 | 25 |
| 141 | Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. Autoimmunity Reviews, 2019, 18, 665-672. | 5.8 | 25 |
| 142 | Treatment options of cognitive impairment in multiple sclerosis. Neurological Sciences, 2010, 31, 265-269. | 1.9 | 24 |
| 143 | Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). PLoS ONE, 2017, 12, e0180651. | 2.5 | 24 |
| 144 | Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience. Multiple Sclerosis and Related Disorders, 2020, 46, 102561. | 2.0 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756. | 7.6 | 24 |
| 146 | Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. Neurotherapeutics, 2021, 18, 1166-1174. | 4.4 | 24 |
| 147 | Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. Journal of the Neurological Sciences, 2009, 286, 109-113. | 0.6 | 23 |
| 148 | Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal. Multiple Sclerosis Journal, 2016, 22, 581-589. | 3.0 | 23 |
| 149 | EAN guideline on palliative care of people with severe, progressive multiple sclerosis. European Journal of Neurology, 2020, 27, 1510-1529. | 3.3 | 23 |
| 150 | Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Journal of the Neurological Sciences, 2018, 391, 72-76. | 0.6 | 22 |
| 151 | Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. Frontiers in Neurology, 2019, 10, 916. | 2.4 | 21 |
| 152 | A possible spatial and temporal cluster of multiple sclerosis in the town of Linguaglossa, Sicily. Journal of Neurology, 2005, 252, 921-925. | 3.6 | 20 |
| 153 | Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. Neurological Sciences, 2013, 34, 1633-1637. | 1.9 | 20 |
| 154 | Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. Journal of the Neurological Sciences, 2014, 338, 128-134. | 0.6 | 20 |
| 155 | Management of dysphagia in multiple sclerosis: current best practice. Expert Review of Gastroenterology and Hepatology, 2019, 13, 47-54. | 3.0 | 20 |
| 156 | Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience. Journal of Neurology, 2019, 266, 411-416. | 3.6 | 20 |
| 157 | Italian consensus on treatment of spasticity in multiple sclerosis. European Journal of Neurology, 2020, 27, 445-453. | 3.3 | 20 |
| 158 | Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 46, 102492. | 2.0 | 20 |
| 159 | The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1349-1359. | 3.3 | 19 |
| 160 | Relationship between urodynamic findings and sexual function in multiple sclerosis patients with lower urinary tract dysfunction. European Journal of Neurology, 2015, 22, 485-492. | 3.3 | 19 |
| 161 | Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. Journal of Neurology, 2020, 267, 3008-3020. | 3.6 | 19 |
| 162 | Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. Multiple Sclerosis Journal, 2021, 27, 430-438. | 3.0 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Clinical features of Sjogrenâ€™s syndrome in patients with multiple sclerosis. Acta Neurologica Scandinavica, 2011, 124, 109-114. | 2.1 | 18 |
| 164 | Offspring Number Does Not Influence Reaching the Disabilityâ€™s Milestones in Multiple Sclerosis: A Seven-Year Follow-Up Study. International Journal of Molecular Sciences, 2016, 17, 234. | 4.1 | 18 |
| 165 | When the word doesn't come out: A synthetic overview of dysarthria. Journal of the Neurological Sciences, 2016, 369, 354-360. | 0.6 | 18 |
| 166 | Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study. Journal of Neurology, 2016, 263, 1802-1809. | 3.6 | 18 |
| 167 | Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. Multiple Sclerosis Journal, 2018, 24, 167-174. | 3.0 | 18 |
| 168 | Box and block test, hand grip strength and nineâ€hole peg test: correlations between three upper limb objective measures in multiple sclerosis. European Journal of Neurology, 2020, 27, 2523-2530. | 3.3 | 18 |
| 169 | Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study). Multiple Sclerosis and Related Disorders, 2020, 42, 102124. | 2.0 | 18 |
| 170 | Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 961-963. | 3.0 | 17 |
| 171 | Multiple Sclerosis in the Mount Etna Region: Possible Role of Volcanogenic Trace Elements. PLoS ONE, 2013, 8, e74259. | 2.5 | 17 |
| 172 | Multiple sclerosis: getting personal with induced pluripotent stem cells. Cell Death and Disease, 2015, 6, e1806-e1806. | 6.3 | 17 |
| 173 | Expression of DNA methylation genes in secondary progressive multiple sclerosis. Journal of Neuroimmunology, 2016, 290, 66-69. | 2.3 | 17 |
| 174 | Retinal Nerve Fiber Layer Thickness and Higher Relapse Frequency May Predict Poor Recovery after Optic Neuritis in MS Patients. Journal of Clinical Medicine, 2019, 8, 2022. | 2.4 | 17 |
| 175 | Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. Disability and Rehabilitation, 2020, 42, 3780-3792. | 1.8 | 17 |
| 176 | The caring experience in multiple sclerosis: Caregiving tasks, coping strategies and psychological wellâ€being. Health and Social Care in the Community, 2020, 28, 236-246. | 1.6 | 17 |
| 177 | CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset. Environmental Research, 2020, 188, 109820. | 7.5 | 17 |
| 178 | The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. Journal of Clinical Psychology in Medical Settings, 2021, 28, 149-160. | 1.4 | 17 |
| 179 | Firstâ€line therapies in lateâ€onset multiple sclerosis: An Italian registry study. European Journal of Neurology, 2021, 28, 4117-4123. | 3.3 | 17 |
| 180 | An exploration of anger phenomenology in multiple sclerosis. European Journal of Neurology, 2009, 16, 1312-1317. | 3.3 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Computer-assisted cognitive rehabilitation on freezing of gait in Parkinsonâ€™s disease: A pilot study. Neuroscience Letters, 2017, 654, 38-41. | 2.1 | 16 |
| 182 | Exploring polypharmacy phenomenon in newly diagnosed relapsingâ€“remitting multiple sclerosis: a cohort ambispective single-centre study. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232098312. | 2.5 | 16 |
| 183 | A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-Î²1a using RebiSmartâ„¢â€”the FUTURE study. Neurological Sciences, 2017, 38, 1999-2005. | 1.9 | 15 |
| 184 | Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Multiple Sclerosis and Related Disorders, 2022, 66, 104025. | 2.0 | 15 |
| 185 | The heritage of glatiramer acetate and its use in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, . | 1.1 | 14 |
| 186 | Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy. Neurological Sciences, 2016, 37, 613-622. | 1.9 | 14 |
| 187 | Risk factors in multiple sclerosis: a population-based caseâ€“control study in Sicily. Background and methods. Neurological Sciences, 2016, 37, 1931-1937. | 1.9 | 13 |
| 188 | An update on the safety of treating relapsing-remitting multiple sclerosis. Expert Opinion on Drug Safety, 2019, 18, 925-948. | 2.4 | 13 |
| 189 | Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Multiple Sclerosis Journal, 2019, 25, 591-600. | 3.0 | 13 |
| 190 | Prevalence of dysphagia in a consecutive cohort of subjects with MS using fibre-optic endoscopy. Neurological Sciences, 2020, 41, 1075-1079. | 1.9 | 13 |
| 191 | Comparing 16 Different Dualâ€“Tasking Paradigms in Individuals With Multiple Sclerosis and Healthy Controls: Working Memory Tasks Indicate Cognitiveâ€“Motor Interference. Frontiers in Neurology, 2020, 11, 918. | 2.4 | 13 |
| 192 | EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis. Journal of Palliative Medicine, 2020, 23, 1426-1443. | 1.1 | 13 |
| 193 | Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Multiple Sclerosis Journal, 2022, 28, 472-479. | 3.0 | 13 |
| 194 | Association Between the Neurogenic Bladder Symptom Score and Urodynamic Examination in Multiple Sclerosis Patients With Lower Urinary Tract Dysfunction. International Neurourology Journal, 2015, 19, 272-277. | 1.2 | 13 |
| 195 | Disability may influence patient willingness to participate in decision making on first-line therapy in multiple sclerosis. Functional Neurology, 2016, 31, 21-3. | 1.3 | 13 |
| 196 | Italian Validation of the 12-Item Multiple Sclerosis Walking Scale. Multiple Sclerosis International, 2015, 2015, 1-6. | 0.8 | 12 |
| 197 | Toxoplasma gondii and multiple sclerosis: a population-based caseâ€“control study. Scientific Reports, 2020, 10, 18855. | 3.3 | 12 |
| 198 | Efficacy of levetiracetam on upper limb movement in multiple sclerosis patients with cerebellar signs: a multicenter doubleâ€blind, placeboâ€controlled, crossover study. European Journal of Neurology, 2020, 27, 2209-2216. | 3.3 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | An update on the pharmacological management of pain in patients with multiple sclerosis. Expert Opinion on Pharmacotherapy, 2020, 21, 2249-2263. | 1.8 | 12 |
| 200 | Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study. Neurological Sciences, 2020, 41, 2905-2913. | 1.9 | 12 |
| 201 | Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsingâ€”remitting multiple sclerosis: 2-year results from the COGIMUS study. Therapeutic Advances in Neurological Disorders, 2009, 2, 67-77. | 3.5 | 11 |
| 202 | Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon Î²-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study. BMC Neurology, 2011, 11, 125. | 1.8 | 11 |
| 203 | Genetic burden of common variants in progressive and bout-onset multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 802-811. | 3.0 | 11 |
| 204 | Magnetic fields exposure from high-voltage power lines and risk of amyotrophic lateral sclerosis in two Italian populations. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 583-589. | 1.7 | 11 |
| 205 | eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54. Multiple Sclerosis Journal, 2019, 25, 856-866. | 3.0 | 11 |
| 206 | Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study. Neurological Sciences, 2019, 40, 1383-1391. | 1.9 | 11 |
| 207 | Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results. Neurological Sciences, 2020, 42, 2837-2845. | 1.9 | 11 |
| 208 | Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis patients. Expert Opinion on Pharmacotherapy, 2020, 21, 1449-1454. | 1.8 | 11 |
| 209 | Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of <scp>REGAIN</scp> and its extension study. Muscle and Nerve, 2021, 64, 662-669. | 2.2 | 11 |
| 210 | Factors driving delayed time to multiple sclerosis diagnosis: Results from a population-based study. Multiple Sclerosis and Related Disorders, 2022, 57, 103361. | 2.0 | 11 |
| 211 | Patients with multiple sclerosis: a burden and cost of illness study. Journal of Neurology, 2022, 269, 5127-5135. | 3.6 | 11 |
| 212 | Management of swallowing disorders in multiple sclerosis. Neurological Sciences, 2006, 27, s338-s340. | 1.9 | 10 |
| 213 | Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories. Quality of Life Research, 2016, 25, 2755-2763. | 3.1 | 10 |
| 214 | Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, . | 1.1 | 10 |
| 215 | Incidence of multiple sclerosis in the province of Catania. A geo-epidemiological study. Environmental Research, 2020, 182, 109022. | 7.5 | 10 |
| 216 | The Dysphagia in Multiple Sclerosis Questionnaire Correlates with Fiber-Optic Endoscopic Examination for Detecting Swallowing Deficits in MS. Dysphagia, 2021, 36, 192-197. | 1.8 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. Journal of Neurology, 2022, 269, 933-944. | 3.6 | 10 |
| 218 | A realâ€world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described â€˜spasticityâ€plus syndromeâ€™. European Journal of Neurology, 2022, 29, 2744-2753. | 3.3 | 10 |
| 219 | A possible spatial and temporal cluster of multiple sclerosis in the town of Linguaglossa, Sicily: an update. Multiple Sclerosis Journal, 2009, 15, 129-130. | 3.0 | 9 |
| 220 | Longitudinal changes in social functioning in mildly disabled patients with relapsingâ€“remitting multiple sclerosis receiving subcutaneous interferon Î²-1a: results from the COGIMUS (COGnitive) Tj ETQq0 0 0 rgB T /Overlock 10 Tf 50 | 3.1 | 9 |
| 221 | Interferon-beta-1a treatment has a positive effect on quality of life of relapsingâ€“remitting multiple sclerosis: Results from a longitudinal study. Journal of the Neurological Sciences, 2014, 337, 180-185. | 0.6 | 9 |
| 222 | Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report. BMC Neurology, 2015, 15, 252. | 1.8 | 9 |
| 223 | Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study. PLoS ONE, 2018, 13, e0200532. | 2.5 | 9 |
| 224 | Italian translation and psychometric validation of the Manual Ability Measure-36 (MAM-36) and its correlation with an objective measure of upper limb function in patients with multiple sclerosis. Neurological Sciences, 2020, 41, 1539-1546. | 1.9 | 9 |
| 225 | Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. Neurotherapeutics, 2021, 18, 905-919. | 4.4 | 9 |
| 226 | Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. Journal of the Neurological Sciences, 2021, 430, 118067. | 0.6 | 9 |
| 227 | Multiple Sclerosis, COVID-19 and Vaccines: Making the Point. Neurology and Therapy, 2021, 10, 627-649. | 3.2 | 9 |
| 228 | Sodium fusidate (fusidin) ameliorates the course of monophasic experimental allergic encephalomyelitis in the Lewis rat. Multiple Sclerosis Journal, 2001, 7, 101-104. | 3.0 | 8 |
| 229 | Examining the validity of the multiple-sclerosis walking scale-12 with Rasch analysis: Results from an Italian study. Multiple Sclerosis and Related Disorders, 2019, 36, 101400. | 2.0 | 8 |
| 230 | Pharmacoeconomics of synthetic therapies for multiple sclerosis. Expert Opinion on Pharmacotherapy, 2019, 20, 1331-1340. | 1.8 | 8 |
| 231 | Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. Multiple Sclerosis Journal, 2021, 27, 1458-1463. | 3.0 | 8 |
| 232 | Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience. Frontiers in Neurology, 2020, 11, 105. | 2.4 | 8 |
| 233 | Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study. Multiple Sclerosis Journal, 2021, 27, 2284-2287. | 3.0 | 8 |
| 234 | Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study. BMC Neurology, 2021, 21, 324. | 1.8 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Job satisfaction among physicians and nurses involved in the management of multiple sclerosis: the role of happiness and meaning at work. Neurological Sciences, 2022, 43, 1903-1910. | 1.9 | 8 |
| 236 | Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. Multiple Sclerosis and Related Disorders, 2022, 57, 103385. | 2.0 | 8 |
| 237 | The effect of air pollution on COVIDâ€19 severity in a sample of patients with multiple sclerosis. European Journal of Neurology, 2022, 29, 535-542. | 3.3 | 8 |
| 238 | Sporadic motor neuron disease in a familial novel SOD1 mutation: Incomplete penetrance or chance association?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 220-222. | 2.1 | 7 |
| 239 | US health insurance is an obstacle to disease-modifying treatments in MS. Neurology, 2016, 87, 346-347. | 1.1 | 7 |
| 240 | Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances. Neurological Sciences, 2016, 37, 437-442. | 1.9 | 7 |
| 241 | Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web) Tj ETQq1 1 0.784314 rgBT /Ov | 1.4 | 7 |
| 242 | Amyotrophic lateral sclerosis spatial epidemiology in the Mount Etna region, Italy. European Journal of Neurology, 2019, 26, e90-e91. | 3.3 | 7 |
| 243 | Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. Neurology, 2022, 98, e1626-e1636. | 1.1 | 7 |
| 244 | Cognitive impairment and â€œinvisible symptomsâ€•are not associated with CCSVI in MS. BMC Neurology, 2013, 13, 97. | 1.8 | 6 |
| 245 | Is the basic trunk control recovery different between stroke patients with right and left hemiparesis?. NeuroRehabilitation, 2014, 35, 215-220. | 1.3 | 6 |
| 246 | Extensive bilateral striopallidodentate calcinosis: a 50Âyears history of hypoparathyroidism presenting like a parkinsonian syndrome. Journal of Neurology, 2016, 263, 1876-1879. | 3.6 | 6 |
| 247 | A Comprehensive Review on CopemylÂ®. Neurology and Therapy, 2017, 6, 161-173. | 3.2 | 6 |
| 248 | Prevalence and Incidence of Multiple Sclerosis in the City of Biancavilla. Neuroepidemiology, 2019, 53, 108-114. | 2.3 | 6 |
| 249 | Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod. Journal of the Neurological Sciences, 2019, 405, 116423. | 0.6 | 6 |
| 250 | Treatment response score to glatiramer acetate or interferon beta-1a. Neurology, 2020, 96, 10.1212/WNL.0000000000010991. | 1.1 | 6 |
| 251 | Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study. Frontiers in Neurology, 2020, 11, 756. | 2.4 | 6 |
| 252 | Objective evaluation of Nintendo Wii Fit Plus balance program training on postural stability in Multiple Sclerosis patients: a pilot study. International Journal of Rehabilitation Research, 2020, 43, 199-205. | 1.3 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment. Expert Review of Neurotherapeutics, 2020, 20, 771-782. | 2.8 | 6 |
| 254 | Listening to the neurological teams for multiple sclerosis: the SMART project. Neurological Sciences, 2020, 41, 2231-2240. | 1.9 | 6 |
| 255 | Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab. CNS Drugs, 2020, 34, 535-543. | 5.9 | 6 |
| 256 | Detection of disability worsening in relapsingâ€remitting multiple sclerosis patients: a realâ€world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. European Journal of Neurology, 2021, 28, 567-578. | 3.3 | 6 |
| 257 | Comparing natural history of early and late onset pediatric multiple sclerosis. Annals of Neurology, 2022, , . | 5.3 | 6 |
| 258 | Pharmacologic management of spasticity in multiple sclerosis. Neurological Sciences, 2006, 27, s310-s315. | 1.9 | 5 |
| 259 | Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide. Acta Neurologica Scandinavica, 2014, 130, e41-e44. | 2.1 | 5 |
| 260 | Multiple sclerosis and amyotrophic lateral sclerosis: a human leukocyte antigen challenge. Neurological Sciences, 2017, 38, 1501-1503. | 1.9 | 5 |
| 261 | Palliative care in progressive multiple sclerosis. Expert Review of Neurotherapeutics, 2017, 17, 123-127. | 2.8 | 5 |
| 262 | Static postural control disturbances among the different multiple sclerosis phenotypes: A Neurocom Balance ManagerÂ® evaluation study. Multiple Sclerosis and Related Disorders, 2018, 26, 46-51. | 2.0 | 5 |
| 263 | Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 914-920. | 1.9 | 5 |
| 264 | Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. Clinical Drug Investigation, 2020, 40, 319-326. | 2.2 | 5 |
| 265 | Early-Onset Alcohol Dependence and Multiple Sclerosis: Diagnostic Challenges. International Journal of Environmental Research and Public Health, 2021, 18, 5588. | 2.6 | 5 |
| 266 | The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study. PLoS ONE, 2016, 11, e0157721. | 2.5 | 5 |
| 267 | Hopelessness in Multiple Sclerosis: Psychological and Organic Correlates. Journal of Psychiatry and Psychiatric Disorders, 2019, 03, . | 0.0 | 5 |
| 268 | Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies. Current Neuropharmacology, 2022, 20, 1978-1987. | 2.9 | 5 |
| 269 | Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature. Journal of Clinical Medicine, 2022, 11, 942. | 2.4 | 5 |
| 270 | Immunological Subsets Characterization in Newly Diagnosed Relapsingâ€“Remitting Multiple Sclerosis. Frontiers in Immunology, 2022, 13, 819136. | 4.8 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | The Antiinflammatory Cytokine Interleukin-13 is not Detectable in the Circulation of Multiple Sclerosis Patients and is not Inducible by Interferon-Î² 1b Treatment, that Neither Modifies its ex vivo Secretion from Peripheral Blood Mononuclear Cells. Autoimmunity, 2000, 32, 265-270. | 2.6 | 4 |
| 272 | Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives. Expert Review of Neurotherapeutics, 2015, 15, 251-268. | 2.8 | 4 |
| 273 | The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study. Multiple Sclerosis and Related Disorders, 2017, 17, 154-171. | 2.0 | 4 |
| 274 | Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience. Expert Review of Clinical Pharmacology, 2018, 11, 531-536. | 3.1 | 4 |
| 275 | <p>BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT<sup>Â®</sup></p>. Patient Preference and Adherence, 2020, Volume 14, 771-779. | 1.8 | 4 |
| 276 | Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. Journal of Neurology, 2021, 268, 1540-1543. | 3.6 | 4 |
| 277 | Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. Journal of Neurology, 2022, 269, 1463-1469. | 3.6 | 4 |
| 278 | Study protocol on advance care planning in multiple sclerosis (ConCure-SM): intervention construction and multicentre feasibility trial. BMJ Open, 2021, 11, e052012. | 1.9 | 4 |
| 279 | Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series. BMC Neurology, 2021, 21, 462. | 1.8 | 4 |
| 280 | A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103909. | 2.0 | 4 |
| 281 | Drug-induced parkinsonism: prevalence, clinical features and follow-up study in three Sicilian communities. Journal of Neurology, 1996, 243, 293-301. | 3.6 | 3 |
| 282 | Non-pharmacologic interventions for spasticity associated with multiple sclerosis. Neurological Sciences, 2006, 27, s316-s319. | 1.9 | 3 |
| 283 | A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. Expert Opinion on Drug Safety, 2015, 14, 1157-1168. | 2.4 | 3 |
| 284 | Lack of association between Toxocara canis and multiple sclerosis: A population-based caseâ€“control study. Multiple Sclerosis Journal, 2020, 26, 258-259. | 3.0 | 3 |
| 285 | Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study. Journal of Neurology, 2020, 267, 1812-1823. | 3.6 | 3 |
| 286 | Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851. | 3.0 | 3 |
| 287 | Italian translation and psychometric validation of the ABILHAND-26 and its correlation with upper limb objective and subjective measures in multiple sclerosis subjects. Multiple Sclerosis and Related Disorders, 2021, 55, 103160. | 2.0 | 3 |
| 288 | Reliability of televisits for patients with mild relapsingâ€“remitting multiple sclerosis in the COVID-19 era. Neurological Sciences, 2022, , 1. | 1.9 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Psychometric properties of the Italian version of the Guy's Neurological Disability Scale. Functional Neurology, 2010, 25, 223-33. | 1.3 | 3 |
| 290 | Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6â€‰years. Multiple Sclerosis Journal, 2022, 28, 2137-2141. | 3.0 | 3 |
| 291 | Paediatric Multiple Sclerosis: A Scoping Review of Patientsâ€™ and Parentsâ€™ Perspectives. Children, 2022, 9, 11. | 1.5 | 3 |
| 292 | Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab. ClinicoEconomics and Outcomes Research, 2009, 1, 45. | 1.9 | 2 |
| 293 | Personalized therapy in multiple sclerosis: state of art and future perspectives. Expert Review of Precision Medicine and Drug Development, 2016, 1, 353-360. | 0.7 | 2 |
| 294 | Hormone replacement in menopausal women with multiple sclerosis. Neurology, 2016, 87, 1430-1431. | 1.1 | 2 |
| 295 | Standardised Frankincense extract: new possible therapeutic option for patients with relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 327-327. | 1.9 | 2 |
| 296 | Lack of evidence for Toxocara infection in Italian myelitis patients. Neurological Sciences, 2020, 41, 239-241. | 1.9 | 2 |
| 297 | Palliative care in multiple sclerosis: European guideline. Multiple Sclerosis Journal, 2020, 26, 1009-1011. | 3.0 | 2 |
| 298 | Living with severe multiple sclerosis: Cost-effectiveness of a palliative care intervention and cost of illness study. Multiple Sclerosis and Related Disorders, 2021, 49, 102756. | 2.0 | 2 |
| 299 | Real world comparison of teriflunomide and dimethyl fumarate in naÃ¯ve relapsing multiple sclerosis patients: Evidence from the Italian MS register. Multiple Sclerosis and Related Disorders, 2022, 58, 103489. | 2.0 | 2 |
| 300 | Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis Journal, 2022, , 135245852210845. | 3.0 | 2 |
| 301 | Multiple Sclerosis Progressive Courses: A Clinical Cohort Long-Term Disability Progression Study. Value in Health, 2022, 25, 1489-1498. | 0.3 | 2 |
| 302 | Ataxia with vitamin E deficiency caused by a new compound heterozygous mutation. Neurological Sciences, 2016, 37, 1571-1572. | 1.9 | 1 |
| 303 | Can new chemical therapies improve the management of multiple sclerosis in children?. Expert Opinion on Pharmacotherapy, 2017, 18, 45-55. | 1.8 | 1 |
| 304 | Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 341-352. | 3.3 | 1 |
| 305 | Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study. Autoimmunity Reviews, 2019, 18, 102365. | 5.8 | 1 |
| 306 | Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. Journal of Neurology, 2019, 266, 3098-3107. | 3.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies. Neurodegenerative Disease Management, 2019, 9, 3-7. | 2.2 | 1 |
| 308 | Reply to Comment on â€œEnvironmental and Occupational Risk Factors of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Studyâ€• International Journal of Environmental Research and Public Health, 2020, 17, 6492. | 2.6 | 1 |
| 309 | Quality of Life in Patients Affected by Multiple Sclerosis: A Systematic Review. , 2010, , 3769-3783. | | 1 |
| 310 | Spinal needle and post-dural puncture headache. Neurological Sciences, 2022, 43, 1467-1468. | 1.9 | 1 |
| 311 | Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study. International Journal of Environmental Research and Public Health, 2022, 19, 6069. | 2.6 | 1 |
| 312 | The Cost-effectiveness of SativexÂ®: The Italian Experience Based on " in Resistant Multiple Sclerosis Spasticity: Discontinuation Study in a Large Population of Italian Patients, SA.FE. Study". International Journal of Neurorehabilitation, 2018, 05, . | 0.1 | 0 |
| 313 | Authorsâ€™ Response to the Letter to the Editor Regarding: A Comprehensive Review on CopemylÂ®. Neurology and Therapy, 2018, 7, 391-393. | 3.2 | 0 |
| 314 | An â€œall-wheel driveâ€•proposal to accelerate clinical research in common and rare neurological diseases. Neurological Sciences, 2020, 41, 789-793. | 1.9 | 0 |
| 315 | Italian validation of the caregiving tasks in multiple sclerosis scale (CTiMSS). Neurological Sciences, 2020, 41, 1881-1889. | 1.9 | 0 |
| 316 | 004â€…Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis. , 2021, , . | | 0 |
| 317 | Aspetti che influenzano lâ€™adesione alla terapia. , 2013, , 81-87. | | 0 |
| 318 | A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon-Î²1a in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2020, 40, 101952. | 2.0 | 0 |
| 319 | Spasticity and Dystonia: A Brief Review. , 0, , . | | 0 |